461 related articles for article (PubMed ID: 12384413)
1. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Blood; 2002 Nov; 100(9):3155-63. PubMed ID: 12384413
[TBL] [Abstract][Full Text] [Related]
2. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958
[TBL] [Abstract][Full Text] [Related]
3. Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions.
Patel SD; Ge Y; Moskalenko M; McArthur JG
J Immunother; 2000; 23(6):661-8. PubMed ID: 11186154
[TBL] [Abstract][Full Text] [Related]
4. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
[TBL] [Abstract][Full Text] [Related]
5. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.
Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ; Darcy PK
J Immunol; 2001 Jan; 166(1):182-7. PubMed ID: 11123291
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy of malignant solid tumors by targeting erbB2 receptors and by activating T cells.
Hu WX; Chen HP; Yu K; Shen LX; Wang CY; Su SZ; Sui WJ; Shan DM; Li HZ
Cancer Biother Radiopharm; 2012 Dec; 27(10):711-8. PubMed ID: 22988969
[TBL] [Abstract][Full Text] [Related]
7. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.
Yun CO; Nolan KF; Beecham EJ; Reisfeld RA; Junghans RP
Neoplasia; 2000; 2(5):449-59. PubMed ID: 11191112
[TBL] [Abstract][Full Text] [Related]
8. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL.
Darcy PK; Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ
J Immunol; 2000 Apr; 164(7):3705-12. PubMed ID: 10725729
[TBL] [Abstract][Full Text] [Related]
9. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.
Moritz D; Wels W; Mattern J; Groner B
Proc Natl Acad Sci U S A; 1994 May; 91(10):4318-22. PubMed ID: 7910405
[TBL] [Abstract][Full Text] [Related]
12. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
Caldwell SA; Ryan MH; McDuffie E; Abrams SI
J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
[TBL] [Abstract][Full Text] [Related]
13. Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signalling chains.
Hombach A; Sircar R; Heuser C; Tillmann T; Diehl V; Kruis W; Pohl C; Abken H
Int J Mol Med; 1998 Jul; 2(1):99-103. PubMed ID: 9854151
[TBL] [Abstract][Full Text] [Related]
14. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
[TBL] [Abstract][Full Text] [Related]
15. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy.
Cheung NK; Guo HF; Modak S; Cheung IY
Hybrid Hybridomics; 2003 Aug; 22(4):209-18. PubMed ID: 14511566
[TBL] [Abstract][Full Text] [Related]
16. A stable single-chain variable fragment expressing transfectoma demonstrates induction of idiotype-specific cytotoxic T-cells during early growth stages of a murine B-lymphoma.
Laxmanan S; Stuart GW; Ghosh SK
Cancer Immunol Immunother; 2001 Oct; 50(8):437-44. PubMed ID: 11726138
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.
Mamalaki A; Gritzapis AD; Kretsovali A; Belimezi M; Papamatheakis J; Perez SA; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Aug; 52(8):513-22. PubMed ID: 12715240
[TBL] [Abstract][Full Text] [Related]
18. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
Hombach A; Wieczarkowiecz A; Marquardt T; Heuser C; Usai L; Pohl C; Seliger B; Abken H
J Immunol; 2001 Dec; 167(11):6123-31. PubMed ID: 11714771
[TBL] [Abstract][Full Text] [Related]
20. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics.
Peng L; Krauss JC; Plautz GE; Mukai S; Shu S; Cohen PA
J Immunol; 2000 Dec; 165(12):7116-24. PubMed ID: 11120842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
